A First‐In‐Human, Randomized, Placebo‐Controlled Single and Multiple Ascending Dose Study of Izicopan (INF904), A Second‐Generation Oral Small Molecule C5a Receptor Inhibitor, in Healthy Participants

Joseph F. Grippo, Anja Pfaff, Zhongli Xu, Isabell Otto, Claus Thielert, Mihaly Imre, Rui Liu, Wantanee Phuapradit, Yazhong Pei, Cuie Chen, Maria Habel, Renfeng Guo, Camilla Chong
Clinical Pharmacology in Drug Development · Wiley · 2026-11-02 · DOI: 10.1002/cpdd.70123

Аннотация

Clinical Pharmacology in Drug Development, Volume 15, Issue 11, November 2026.

Читать у издателя →

Похожие статьи